The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Wall Street’s major averages ended slightly lower last week, after posting back-to-back record closes as market participants juggled Trump's tariff announcements against a healthy appetite for ...

Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...